摘要
2型糖尿病发病率逐年递增,随着病情发展可能出现心脏、肾脏、血管、神经等方面的并发症,其中心血管并发症是2型糖尿病患者死亡的重要原因。钠-葡萄糖共转运蛋白双重抑制剂索格列净可以减少2型糖尿病患者心血管并发症的发生,并改善心脏预后,提高患者生存率。
The incidence of type 2 diabetes mellitus(T2DM)is increasing,and its development can result in several complications,including cardiac,renal,vascular,and neurological problems.Cardiovascular complications are the leading cause of death in patients with T2DM.Sotagliflozin,a dual SGLT inhibitor,may reduce cardiovascular complications,and improve cardiac outcome and patients'survival rate.
作者
王霞
张凌云
宋守君
Wang Xia;Zhang Lingyun;Song Shoujun(Second School of Clinical Medicine,Binzhou Medical University,Department of General Medicine,Yantai Hospital Affilated to Binzhou Medical University,Yantai 264000,China)
出处
《国际医药卫生导报》
2024年第13期2141-2144,共4页
International Medicine and Health Guidance News
关键词
2型糖尿病
心血管并发症
索格列净
进展
Type 2 diabetes mellitus
Cardiovascular complications
Sotagliflozin
Progress